Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Tango Therapeutics said it will present updated vopimetostat and RAS(ON) combination data at the ESMO Congress 2026. The company also plans a PDAC-focused investor webcast on October 23, 2026, at 7:30 a.m. ET.
Tango Therapeutics will present updated Phase 1/2 vopimetostat combination data at the ESMO Congress in Madrid on Oct. 25, 2026. The study evaluates vopimetostat with daraxonrasib or zoldonrasib in patients with MTAP-deleted, RAS-mutant metastatic pancreatic cancer or non-small cell lung cancer. A pancreatic cancer-foc
The company plans to present updated vopimetostat and RAS(ON) combination data at the European Society for Medical Oncology Congress in 2026.